Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

First International Summit on Interventional Pharmacoeconomics

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Issues in Oncology

The ASCO Post Staff

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Jun

Today In Oncology

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Related Videos

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Existing Cardioprotective Agents Provide Limited Benefits for Patients With Cancer

First-Line Avelumab Plus Methotrexate in Low-Risk Gestational Trophoblastic Tumors

CNS Prophylaxis With High-Dose Methotrexate in Ultra–High-Risk Large B-Cell Lymphoma

FDA Approves Sacituzumab Govitecan-hziy as Monotherapy and in Combination With Pembrolizumab for First-Line Treatment of TNBC

Changes in AI Mammogram Risk Scores Over Time May Help to Predict Future Breast Cancer